The Impact of COVID-19 is included in Anti-Tuberculosis Therapeutics Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Anti-Tuberculosis Therapeutics Trends and Forecast
The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Anti-Tuberculosis Therapeutics by Segment
The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.
Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:
• Active TB
• Latent TB
• Others
Anti-Tuberculosis Therapeutics Market by Drug Classes [Shipment Analysis by Value from 2018 to 2030]:
• Isoniazid
• Rifampin
• Ethambutol
• Pyrazinamide
• Fluoroquinolones
• Bedaquiline
• Amynoglycosides
• Thioamides
• Cyclic Peptides
• Others
Anti-Tuberculosis Therapeutics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
• Hospitals
• Specialty Clinics
• Homecare
• Others
Anti-Tuberculosis Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Anti-Tuberculosis Therapeutics Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-
• Lupin
• Macleods
• Otsuka
• Johnson & Johnson
• Sequella
• Novartis
• Akorn
• Fresenius Se
• Viatris
Anti-Tuberculosis Therapeutics Market Insights
Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Within this market, hospitals will remain the largest segment due to .
APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Features of the Global Anti-Tuberculosis Therapeutics Market
Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region in terms of value ($B).
Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and regions for the anti-tuberculosis therapeutics market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the anti-tuberculosis therapeutics market size?
Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.
Q.2 What is the growth forecast for anti-tuberculosis therapeutics market?
Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?
Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
Q4. What are the major segments for anti-tuberculosis therapeutics market?
Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.
Q5. Who are the key Anti-Tuberculosis Therapeutics Market companies?
Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:
• Lupin
• Macleods
• Otsuka
• Johnson & Johnson
• Sequella
• Novartis
• Akorn
• Fresenius SE
• Viatris
Q6. Which anti-tuberculosis therapeutics market segment will be the largest in future?
Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Q7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the anti-tuberculosis therapeutics market by type (active TB, latent LB, and others), drug classes (isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, bedaquiline, amynoglycosides, thioamides, cyclic peptides, and others), end use (hospitals, specialty clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Anti-Tuberculosis Therapeutics Market, Anti-Tuberculosis Therapeutics Market Size, Anti-Tuberculosis Therapeutics Market Growth, Anti-Tuberculosis Therapeutics Market Analysis, Anti-Tuberculosis Therapeutics Market Report, Anti-Tuberculosis Therapeutics Market Share, Anti-Tuberculosis Therapeutics Market Trends, Anti-Tuberculosis Therapeutics Market Forecast, Anti-Tuberculosis Therapeutics Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Anti-Tuberculosis Therapeutics Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Anti-Tuberculosis Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Anti-Tuberculosis Therapeutics Market by Type
3.3.1: Active TB
3.3.2: Latent TB
3.3.3: Others
3.4: Global Anti-Tuberculosis Therapeutics Market by Drug Classes
3.4.1: Isoniazid
3.4.2: Rifampin
3.4.3: Ethambutol
3.4.4: Pyrazinamide
3.4.5: Fluoroquinolones
3.4.6: Bedaquiline
3.4.7: Amynoglycosides
3.4.8: Thioamides
3.4.9: Cyclic Peptides
3.5: Global Anti-Tuberculosis Therapeutics Market by End Use
3.5.1: Hospitals
3.5.2: Specialty Clinics
3.5.3: Homecare
3.5.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Anti-Tuberculosis Therapeutics Market by Region
4.2: North American Anti-Tuberculosis Therapeutics Market
4.2.2: North American Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.3: European Anti-Tuberculosis Therapeutics Market
4.3.1: European Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.3.2: European Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.4: APAC Anti-Tuberculosis Therapeutics Market
4.4.1: APAC Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.4.2: APAC Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.5: ROW Anti-Tuberculosis Therapeutics Market
4.5.1: ROW Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.5.2: ROW Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Type
6.1.2: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Drug Classes
6.1.3: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by End Use
6.1.4: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Region
6.2: Emerging Trends in the Global Anti-Tuberculosis Therapeutics Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Anti-Tuberculosis Therapeutics Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Anti-Tuberculosis Therapeutics Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Lupin
7.2: Macleods
7.3: Otsuka
7.4: Johnson & Johnson
7.5: Sequella
7.6: Novartis
7.7: Akorn
7.8: Fresenius SE
7.9: Viatris
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Anti-Tuberculosis Therapeutics Market Report.